Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS
Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS
复制标题
DOI：
10.1258/0956462981922098
复制
发表时间：
1998-04-01
影响因子：
1.4
通讯作者：
Leen, C
中科院分区：
文献类型：
--
作者：
Dhillon, B;Kamal, A;Leen, C
一种新的治疗方法，玻璃体内更昔洛韦植入物（Vitrasert（R）），被用于治疗艾滋病患者的巨细胞病毒（CMV）视网膜炎，当它不可能继续全身治疗或疾病进展明显，尽管传统的静脉治疗。回顾9个人的眼科和一般健康数据，手术记录和眼底照片的Vitrasert植入手术在爱丁堡。2例患者接受了双侧置换植入物手术。视力，伴随抗CMV治疗，植入和视网膜炎的控制的并发症记录，直到最后follow-up. CMV视网膜炎的控制在所有个人在术后一个月实现，并保持控制的平均时间为5.8个月。除2例患者的2只眼发生非进行性黄斑水肿外，所有患者的术后并发症均为轻度和一过性。在本系列中，未发生手术导致的盲性并发症，也未观察到视网膜脱离。当系统治疗无法控制疾病进展时，玻璃体植入术是CMV视网膜炎可接受且耐受性良好的治疗方法。
A novel form of therapy, the intravitreal ganciclovir implant (Vitrasert(R)), was used to treat cytomegalovirus (CMV) retinitis in AIDS, when it was not possible to continue systemic therapy or disease progression was evident despite conventional intravenous treatment.A review of the ophthalmic and general health data, operative records and fundus photographs of 9 individuals who had Vitrasert implantation surgery in Edinburgh. Two patients received bilateral replacement implant procedures. Visual acuity, concomitant anti-CMV therapy, complications of implantation and control of retinitis were documented until final follow-up.Control of CMV retinitis was achieved in all individuals at one month postoperatively and remained controlled for a mean period of 5.8 months. Postoperative complications were mild and transient in all but 2 eyes of 2 patients who developed non-progressive macula oedema. Blinding complications as a result of surgery were not encountered and retinal detachment was not observed in this series.Vitrasert implantation is an acceptable and well tolerated treatment for CMV retinitis when systemic therapy fails to control disease progression.